NASDAQ:BVXV BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free BVXV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.26▼$1.5952-Week Range N/AVolume23,000 shsAverage Volume127,289 shsMarket Capitalization$2.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BiondVax Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About BiondVax Pharmaceuticals Stock (NASDAQ:BVXV)BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details BVXV Stock News HeadlinesMarch 23, 2024 | seekingalpha.comSCNI Scinai Immunotherapeutics Ltd.October 4, 2023 | finance.yahoo.comScinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023May 6, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.September 19, 2023 | finance.yahoo.comScinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct OfferingSeptember 15, 2023 | finance.yahoo.comScinai Immunotherapeutics Announces $1.33 Million Registered Direct OfferingSeptember 13, 2023 | finance.yahoo.comScinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical ResultsSeptember 11, 2023 | finance.yahoo.comScinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in BostonSeptember 6, 2023 | financialpost.comBiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsMay 6, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.August 11, 2023 | finanznachrichten.deBiondVax Pharmaceuticals Ltd.: BiondVax Reports Second Quarter Financial Results and Provides Business UpdateAugust 11, 2023 | finance.yahoo.comBiondVax Reports Second Quarter Financial Results and Provides Business UpdateAugust 2, 2023 | finanznachrichten.deBiondVax Pharmaceuticals Ltd.: Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesAugust 1, 2023 | finance.yahoo.comNasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesJuly 28, 2023 | theglobeandmail.comBiondVax (NASDAQ: BVXV) Leveraging NanoAb Pipeline to Target Large MarketsJuly 11, 2023 | finance.yahoo.comIBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.July 6, 2023 | finance.yahoo.comBVXV - BiondVax Pharmaceuticals Ltd.June 5, 2023 | finance.yahoo.comBiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisMay 30, 2023 | finance.yahoo.comBVXV: Developing anti-IL-17 NanoAbMay 15, 2023 | finanznachrichten.deBiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business UpdateMay 15, 2023 | msn.comBiondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73May 15, 2023 | finance.yahoo.comBiondVax Announces First Quarter 2023 Financial Results and Provides Business UpdateApril 20, 2023 | theglobeandmail.comBiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership TeamApril 18, 2023 | finanznachrichten.deBiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateApril 4, 2023 | marketwatch.comBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing TherapiesMarch 26, 2023 | marketwatch.comBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 VariantsMarch 16, 2023 | finance.yahoo.comBiondVax to Present at BIO-Europe SpringMarch 6, 2023 | finance.yahoo.comIBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir ReichmanSee More Headlines Receive BVXV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2022Today5/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BVXV CUSIPN/A CIK1611747 Webwww.biondvax.com Phone9723029302529Fax972-8930-2531Employees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-346.36% Return on Assets-29.52% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.81) per share Price / BookN/AMiscellaneous Outstanding Shares1,870,000Free Float1,755,000Market Cap$2.54 million OptionableNot Optionable Beta2.37 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Amir Reichman M.B.A. (Age 47)M.Sc., CEO & Director Comp: $562.5kMr. Elad Mark B.Sc. (Age 41)Eng., M.B.A., Chief Operating Officer Comp: $277.02kDr. Tamar Ben-Yedidia Ph.D. (Age 59)Chief Science Officer Comp: $314.92kMr. Uri Ben-Or CPA (Age 53)CPA, M.B.A., MBA, Chief Financial Officer Mr. Joshua E. Phillipson B.Sc.M.B.A., Director of Communications & Investor RelationsMs. Moran Ahdout Fruchter L.L.B.Chief of StaffMs. Dalit Weinstein FischerVP and Head of Technical R&DMore ExecutivesKey CompetitorsEiger BioPharmaceuticalsNASDAQ:EIGRWindtree TherapeuticsNASDAQ:WINT9 Meters BiopharmaNASDAQ:NMTREnveric BiosciencesNASDAQ:ENVBInhibikase TherapeuticsNYSE:IKTView All Competitors BVXV Stock Analysis - Frequently Asked Questions How were BiondVax Pharmaceuticals' earnings last quarter? BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its earnings results on Monday, March, 28th. The company reported ($2.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $1.80. When did BiondVax Pharmaceuticals' stock split? BiondVax Pharmaceuticals's stock reverse split before market open on Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of BiondVax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA). When did BiondVax Pharmaceuticals IPO? BiondVax Pharmaceuticals (BVXV) raised $10 million in an initial public offering on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO. This page (NASDAQ:BVXV) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiondVax Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
